References
- Iqvia.com [Internet]. IQVIA: Global Use Of Medicines 2023 – Outlook To 2027; 2023 [cited 2023 Dec 21]. Available from: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/the-global-use-of-medicines-2023
- Giuliani J, Fiorica F, Albanese V, et al. Financial toxicity and cancer treatments: help from biosimilars - the explanatory case of bevacizumab. Eur J Cancer. 2021;143:40–42. doi: 10.1016/j.ejca.2020.11.004
- Giuliani J, Bonetti A. The economic impact of biosimilars in oncology and hematology: the case of Trastuzumab and Rituximab. Anticancer Res. 2019;39(7):3971–3973. doi: 10.21873/anticanres.13552
- Iqvia.com [Internet]. IQVIA: Global Medicine Spending and usage trends. Outlook to 2025 2021 [cited 2023 Dec 21]. Available from: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-medicine-spending-and-usage-trends-outlook-to-2025.
- Németh B, Csanádi M, Inotai A, et al. Access to high-priced medicines in lower-income countries in the WHO European Region. Oslo medicines initiative technical report. Copenhagen: WHO Regional Office for Europe; 2022. [cited 2023 Dec 21]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK587815/
- Cohen HP, Turner M, McCabe D, et al. Future evolution of biosimilar development by application of Current science and available evidence: the Developer’s perspective. BioDrugs. 2023;37(5):583–593.
- Wolff-Holz E, Tiitso K, Vleminckx C, et al. Evolution of the EU biosimilar framework: past and future. BioDrugs. 2019;33(6):621–634. doi: 10.1007/s40259-019-00377-y
- Bielsky MC, Cook A, Wallington A, et al. Streamlined approval of biosimilars: moving on from the confirmatory efficacy trial. Drug Discov Today. 2020;9:S1359–6446(20)30343–3. doi: 10.1016/j.drudis.2020.09.006
- Medicinesforeurope.com [Internet] Medicines for Europe: market review - European biosimilar medicine markets. Policy Overview; 2023. [cited 2023 Dec 21]. Available from: https://www.medicinesforeurope.com/wp-content/uploads/2023/09/Biosimilars-Market-Review-2023-final-06-09-2023.pdf
- Moorkens E, Barcina Lacosta T, Vulto AG, et al. Learnings from regional market dynamics of originator and biosimilar infliximab and Etanercept in Germany. Pharmaceuticals. 2020;13(10):324. doi: 10.3390/ph13100324
- Barcina Lacosta T, Vulto AG, Huys I, et al. An exploration of biosimilar TNF- alpha inhibitors uptake determinants in hospital environments in Italy, Portugal, and Spain. Front Med. 2023;9:1029040. doi: 10.3389/fmed.2022.1029040
- Inotai A, Ágh T, Karpenko AW, et al. Behind the subcutaneous trastuzumab hype: evaluation of benefits and their transferability to Central Eastern European countries. Expert Rev Pharmacoecon Outcomes Res. 2019;19(2):105–113. doi: 10.1080/14737167.2019.1554437
- Maniadakis N, Holtorf AP, Otávio Corrêa J, et al. Shaping pharmaceutical tenders for effectiveness and sustainability in countries with expanding healthcare coverage. Appl Health Econ Health Policy. 2018;16(5):591–607. doi: 10.1007/s40258-018-0405-7
- Barbier L, Simoens S, Soontjens C, et al. Off-patent biologicals and biosimilars tendering in Europe—A proposal towards more sustainable practices. Pharmaceuticals. 2021;14(6):499. doi: 10.3390/ph14060499
- Németh G, Mágó ML, Kaló Z, et al. A concept for multi-winner tenders for medicinal products with balancing between ecient prices, long-term competition and sustainability of supply. Front Med. 2023;10:1282698. doi: 10.3389/fmed.2023.1282698
- Iqvia.com [Internet]. IQVIA: biosimilar scorecard 2020 Norway; 2020 [cited 2023 Dec 21] Available from: https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/country-scorecards-for-biosimilar-sustainability/iqvia-biosimilar-scorecard-norway.pdf?la=en&hash=587B419F8E3AD460F607D9D84C2FECE0
- ohe.org [Internet]. Napier M, Kourouklis D, Cole A, Cookson G: The dynamics of drug shortages. OHE Contract Research; 2024 [cited 2024 Mar 18]. Available from: https://www.ohe.org/publications/the-dynamic-of-drug-shortages.
- Iqvia.com [Internet]. IQVIA: assessing the biosimilar void: achieving sustainable levels of biosimilar competition in Europe; 2023 [cited 2023 Dec 21]. Available from: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/assessing-the-biosimilar-void
- futuros.gob.es [Internet]. Spain’s National Office of Foresight and strategy: resilient EU2030; 2023 [cited 2023 Dec 21]. Available from: https://futuros.gob.es/sites/default/files/2023-09/RESILIENTEU2030.pdf
- Alnaqbi KA, Bellanger A, Brill A, et al. An international comparative analysis and roadmap to sustainable biosimilar markets. Front Pharmacol. 2023;14:1188368. doi: 10.3389/fphar.2023.1188368
- Simoens S, Le Pen C, Boone N, et al. How to realize the potential of off-patent biologicals and biosimilars in Europe? Guidance to policymakers. GaBI J. 2018;7(2):70–74. doi: 10.5639/gabij.2018.0702.014
- Kim Y, Kwon HY, Godman B, et al. Uptake of biosimilar infliximab in the UK, France, Japan, and Korea: budget savings or market expansion across countries? Front Pharmacol. 2020;11:970. doi: 10.3389/fphar.2020.00970
- Barcina Lacosta T, Vulto AG, Turcu-Stiolica A, et al. Qualitative analysis of the design and implementation of benefit-sharing programs for biologics across Europe. BioDrugs. 2022;36(2):217–229. doi: 10.1007/s40259-022-00523-z
- biosimilars-nederland.nl [Internet] Vulto A: IBN beleidspunt: duurzaamheid van de biosimilar-markt. Initiatiefgroep Biosimilars Nederland; 2021 [cited 2023 Dec 21]. Available from: https://www.biosimilars-nederland.nl/wp-content/uploads/2021_09_14-Kerngroep-IBN-Duurzaamheid-BS-markt_AGVulto_Vs21i13.pdf
- Rickard I, Carmona E, Lessing T, et al. Economic evaluation of adalimumab biosimilars and JAK inhibitors for the treatment of moderate-to-severe rheumatoid arthritis. Poster presented at: ISPOR International Conference; 2022 May 15–18; Washington DC, USA. [cited 2023 Dec 21] Available from: https://www.valueinhealthjournal.com/article/S1098-3015(22)00541-1/fulltext